Xeris Biopharma Holdings Inc
(STU:2B30)
€
7.23
+0.11 (+1.49%)
Market Cap: 1.25 Bil
Enterprise Value: 1.38 Bil
PE Ratio: 137.83
PB Ratio: 110.27
GF Score: 74/100 Xeris Biopharma Holdings Inc at Barclays Global Healthcare Conference Transcript
Mar 11, 2026 / 03:30PM GMT
Release Date Price:
€4.88
(-0.85%)
Jenna Davidner
Barclays Services Corp - Equity Analyst
All right, I think we're all set. Good morning. Yes, it's still morning. Good morning, and welcome to the Barclays Miami Healthcare Conference. My name's Jenna Davidner. I'm one of the analysts here on the specialty pharmaceuticals team. And on stage with me, I have Xeris Biopharma, and from the company, we have the CEO, John Shannon; and on the end, we have Steve Pieper, the CFO.
Thank you guys for joining, and welcome to the conference.
John Shannon
Xeris Biopharma Holdings Inc - President, Chief Operating Officer
Thanks for having us.
Questions & Answers
Jenna Davidner
Barclays Services Corp - Equity Analyst
So maybe just to level set the conversation, John, can you just give investors that are less familiar a brief overview of the company and your current product portfolio?
John Shannon
Xeris Biopharma Holdings Inc - President, Chief Operating Officer
Yeah, I'll just go really high level
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot